Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (321-330 of 564) with videos related to

Pageof 57
Sort By:
Future Oncology (London, England)|August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
The Journal of Urology|February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical TrialMaha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Urology|February 7, 2007
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancerCora N Sternberg, S Machele Donat, Joaquim Bellmunt, et al.
Cancer|June 19, 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 studyDavid J Vaughn, Sandy Srinivas, Walter M Stadler, et al.
Cancer|March 26, 2003
Can patient selection for bladder preservation be based on response to chemotherapy?Cora N Sternberg, Vito Pansadoro, Fabio Calabrò, et al.
European Urology|January 1, 1988
Chemotherapeutic management of invasive bladder carcinomaC N Sternberg, A Yagoda, H I Scher, et al.
Frontiers in Oncology|November 29, 2012
An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumorsEugenio Donato Di Paola, Silvia Alonso, Rosa Giuliani, et al.
BJU International|January 4, 2012
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatmentAndrea Mancuso, Eugenio Donato Di Paola, Alvaro Leone, et al.
The Journal of Urology|March 1, 1985
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
Cancer|December 15, 1989
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseC N Sternberg, A Yagoda, H I Scher, et al.
Pageof 57

Showing results (321-330 of 564) with videos related to

Sort By:
Pageof 57
Future Oncology (London, England)|August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
The Journal of Urology|February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical TrialMaha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Urology|February 7, 2007
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancerCora N Sternberg, S Machele Donat, Joaquim Bellmunt, et al.
Cancer|June 19, 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 studyDavid J Vaughn, Sandy Srinivas, Walter M Stadler, et al.
Cancer|March 26, 2003
Can patient selection for bladder preservation be based on response to chemotherapy?Cora N Sternberg, Vito Pansadoro, Fabio Calabrò, et al.
European Urology|January 1, 1988
Chemotherapeutic management of invasive bladder carcinomaC N Sternberg, A Yagoda, H I Scher, et al.
Frontiers in Oncology|November 29, 2012
An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumorsEugenio Donato Di Paola, Silvia Alonso, Rosa Giuliani, et al.
BJU International|January 4, 2012
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatmentAndrea Mancuso, Eugenio Donato Di Paola, Alvaro Leone, et al.
The Journal of Urology|March 1, 1985
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
Cancer|December 15, 1989
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseC N Sternberg, A Yagoda, H I Scher, et al.
Pageof 57